Atazanavir

證據等級: L5

預測適應症: 6 個

Atazanavir: From HIV-1 Infection to Simian Immunodeficiency Virus Infection

One-Sentence Summary

Atazanavir is an HIV-1 protease inhibitor used as part of antiretroviral therapy for HIV-1 infection (inferred from trial context in this evidence pack; no formal indication record exists because the drug is not marketed in Norway). The TxGNN model's top-ranked prediction is Simian Immunodeficiency Virus (SIV) Infection, a lentivirus infection of macaques, supported by only 1 preclinical publication and 0 clinical trials — evidence that is preclinical/mechanistic only, not clinically actionable.

⚠️ Important caveat: Ranks 2–4 in this prediction set (feline AIDS, a rare neurodevelopmental disorder, and an obsolete hyperlipidemia term) have no meaningful mechanistic or evidentiary support and should not be pursued. Rank 5 ("AIDS related complex") does have strong evidence (2 completed Phase 3 RCTs, L1), but this reflects the drug's already-established core HIV/AIDS indication, not a genuine repurposing opportunity.

Quick Overview

Item	Content
Original Indication	HIV-1 infection (antiretroviral therapy) — inferred from clinical trial context; not formally on file as no Taiwan/Norway license exists
Predicted New Indication	Simian Immunodeficiency Virus (SIV) Infection
TxGNN Prediction Score	99.98%
Evidence Level	L4
Norway Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed DrugBank MOA data was not available in this evidence pack (flagged as a High-severity data gap, DG002). However, context embedded in the evidence itself (clinical trial titles and the rationale for rank 5) indicates atazanavir is an HIV-1 protease inhibitor that blocks cleavage of the Gag-Pol polyprotein, preventing viral maturation — the pharmacological basis for its established use in HIV-1 infection.

SIV and HIV both belong to the lentivirus genus and share structural homology in their protease enzymes. This gives a theoretical rationale for cross-species protease inhibition, which is the basis of TxGNN's high similarity score. However, SIV infection is exclusively a non-human primate disease model used in translational HIV research (e.g., macaque studies of CNS viral reservoirs). It is not a human clinical indication, so this prediction has research value only — it cannot be advanced as a human drug repurposing candidate regardless of mechanistic plausibility.

By contrast, rank 5 ("AIDS related complex") is directly supported by two completed Phase 3 RCTs (NCT00035932, n=571; NCT01099579, n=82) and reflects atazanavir's core, already-approved pharmacology rather than a new indication. This is useful context but does not constitute "repurposing" in the sense this report is meant to evaluate.

Clinical Trial Evidence

Currently no related clinical trials registered for Simian Immunodeficiency Virus Infection.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
20497048	2010	Preclinical (macaque model)	The Journal of Infectious Diseases	HAART-treated SIV-infected macaques showed reduced CNS viral replication and inflammation, but persistent viral DNA in the CNS despite plasma viral suppression — an animal translational model finding, not direct evidence for a human indication.

Norway Market Information

Atazanavir is not currently marketed in Norway (market status: 未上市 / Not marketed). There are no drug license records (total_licenses = 0), so no authorization table can be produced.

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug-drug interaction data were not available in this evidence pack — flagged as a Blocking-severity data gap, DG001, that prevents entry into the S1 safety pre-assessment stage.)

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction (SIV infection) targets a non-human disease model and is supported only by a single preclinical publication with no clinical trials (L4, S0 decision stage) — insufficient for repurposing consideration. Ranks 2–4 lack any credible mechanistic or evidentiary basis. Rank 5, while strongly supported (L1), represents the drug's existing core indication rather than a new opportunity, so it does not change the overall recommendation for this repurposing candidate.

To proceed, the following is needed:

TFDA-equivalent (or Norwegian) package insert warnings/contraindications (DG001 — Blocking; required before any S1 safety pre-assessment)
Confirmed mechanism-of-action data from DrugBank (DG002 — High priority; needed to properly assess mechanistic plausibility)
If pursuing translational research value, a defined path from the SIV macaque model to a genuine human indication (e.g., HIV-associated neurocognitive disorder), since SIV infection itself is not a human disease target
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.